Menu

Novel Cystic Fibrosis Drug Approved

After a lightning-fast approval, the first medicine to treat an underlying cause of the disorder hits the market.

Feb 1, 2012
Megan Scudellari

The US Food and Drug Administration has approved the first drug to treat a genetic cause of cystic fibrosis (CF), the agency announced yesterday (January 31). The drug, Vertex’s Kalydeco, was granted approval in approximately 3 months, twice as fast as normal FDA priority reviews and one of the fastest FDA approvals ever, according to a Vertex press release. It is one of the first drugs approved to correct a specific genetic defect.

CF, the most common fatal genetic disease in the Caucasian population, is caused by defective or missing CFTR proteins, cell receptors that regulate ion and water transport in and out of cells. Lack of CFTR proteins results in the buildup of a thick, sticky mucus in the lungs. Kalydeco, a twice-a-day pill, is approved for use in people with the G551D mutation in the CFTR gene. Approximately 1,200 people in the United States, or 4 percent of those with CF, have the G551D mutation.

"Kalydeco is an excellent example of the promise of personalized medicine—targeted drugs that treat patients with a specific genetic makeup," FDA Commissioner Margaret Hamburg said in an FDA press release.

“Even though this drug isn’t for the majority of people, it proves that you can look at the mistake in the genes and design a drug in a rational way that will fix the problem,” Drucy Borowitz, director of the cystic fibrosis program at the State University of New York at Buffalo, told the Associated Press.

In two phase III trials involving 213 patients with the G551D mutation, the drug resulted in significant and sustained improvements in lung function. It is not effective in patients with other CFTR mutations, including F508, the most common CFTR mutation that results in CF.

Kalydeco, which begins shipping to pharmacies this week, will cost patients $294,000 per year, reported FierceBiotech, which is typical for a drug targeting a small disease population such as this. Vertex will provide Kalydeco for free to those who do not have insurance and have an annual household income of $150,000 or less, the company said.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening